Epicrispr Biotechnologies has secured $68 million in a Series B funding round to initiate clinical trials for its first-in-class disease-modifying epigenetic neuromuscular therapy targeting Facioscapulohumeral muscular dystrophy (FSHD). The funding was backed by notable investors, including Chip Wilson, the founder of Lululemon. This investment aims to advance the company's innovative approach to treating this rare muscle disease through epigenetic editing. In related news, Turn Bio has acquired Harvard-developed therapeutic delivery technology to enhance mRNA-based epigenetic reprogramming therapies, with plans to target skin rejuvenation in clinical trials set for 2026. This acquisition is expected to broaden the scope of potential targets for epigenetic reprogramming.